Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Different malabsorptive obesity surgery interventions result in distinct postprandial amino acid metabolomic signatures

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gastric bypass with different biliopancreatic limb lengths results in similar post-absorptive metabolomics profiles

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genetic Determinants of Weight Loss After Bariatric Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1-Alpha Mutation Carriers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 μg, 150 μg, and 300 μg) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 μg dose seems sufficient to prevent hypoglycemia.

OriginalsprogEngelsk
TidsskriftObesity Surgery
ISSN0960-8923
DOI
StatusE-pub ahead of print - 10 nov. 2019

ID: 58351450